Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.

MLA

Pierrillas, Philippe B., et al. “Translational Approach from Preclinical to Clinical: Comparison of Dose Finding Methods of a New Bcl2 Inhibitor Using PK-PD Modeling and Interspecies Extrapolation.” Investigational New Drugs, vol. 38, no. 6, Dec. 2020, pp. 1796–806. EBSCOhost, https://doi.org/10.1007/s10637-020-00953-y.

APA

Pierrillas, P. B., Henin, E., Ogier, J., Amiel, M., Kraus-Berthier, L., Chenel, M., Bouzom, F., & Tod, M. (2020). Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation. Investigational New Drugs, 38(6), 1796–1806. https://doi.org/10.1007/s10637-020-00953-y

Chicago

Pierrillas, Philippe B, Emilie Henin, Julien Ogier, Magali Amiel, Laurence Kraus-Berthier, Marylore Chenel, François Bouzom, and Michel Tod. 2020. “Translational Approach from Preclinical to Clinical: Comparison of Dose Finding Methods of a New Bcl2 Inhibitor Using PK-PD Modeling and Interspecies Extrapolation.” Investigational New Drugs 38 (6): 1796–1806. doi:10.1007/s10637-020-00953-y.